CA3069515A1 - Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment - Google Patents

Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment Download PDF

Info

Publication number
CA3069515A1
CA3069515A1 CA3069515A CA3069515A CA3069515A1 CA 3069515 A1 CA3069515 A1 CA 3069515A1 CA 3069515 A CA3069515 A CA 3069515A CA 3069515 A CA3069515 A CA 3069515A CA 3069515 A1 CA3069515 A1 CA 3069515A1
Authority
CA
Canada
Prior art keywords
cells
cgamp
cell
sample
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069515A
Other languages
English (en)
French (fr)
Inventor
Lewis C. Cantley
Bryan NGO
Samuel F. BAKHOUM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Memorial Sloan Kettering Cancer Center
Original Assignee
Cornell University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, Memorial Sloan Kettering Cancer Center filed Critical Cornell University
Publication of CA3069515A1 publication Critical patent/CA3069515A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
CA3069515A 2017-07-10 2018-07-10 Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment Pending CA3069515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
US62/530,661 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
CA3069515A1 true CA3069515A1 (en) 2019-01-17

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069515A Pending CA3069515A1 (en) 2017-07-10 2018-07-10 Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment

Country Status (12)

Country Link
US (2) US11821042B2 (https=)
EP (1) EP3652349A1 (https=)
JP (1) JP7197556B2 (https=)
KR (1) KR20200037796A (https=)
CN (1) CN111295454A (https=)
AU (1) AU2018300007A1 (https=)
BR (1) BR112020000477A2 (https=)
CA (1) CA3069515A1 (https=)
IL (1) IL271849A (https=)
MX (1) MX2020000406A (https=)
SG (1) SG11202000132WA (https=)
WO (1) WO2019014246A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045155A1 (en) * 2016-09-02 2018-03-08 The Board Of Trustees Of The University Of Illinois Kif13b-derived peptide and method of inhibiting angiogenesis
AU2018300007A1 (en) 2017-07-10 2020-02-27 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
CN114761804A (zh) * 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
US20230346785A1 (en) * 2020-02-19 2023-11-02 Ibmc - Instituto De Biologia Molecular E Celular 4-PYRROLIDIN-1-Yl-5-P-TOLYL-THIENO[2,3-D] PYRIMIDINE FOR USE IN THE TREATMENT OF AGING-ASSOCIATED AND PREMATURE AGING DISEASES THROUGH RESTORED CHROMOSOMAL STABILITY AND INHIBITION OF CELLULAR SENESCENCE
JP2023534375A (ja) * 2020-05-28 2023-08-09 王 道祥 細胞病理学的サンプルに対する多重染色切片調製法
AU2021336887A1 (en) * 2020-09-02 2023-03-30 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsDNA signaling in chromosomally unstable cancers
US20240207248A1 (en) * 2021-04-23 2024-06-27 Baruch S. Blumberg Institute Methods, kits and compositions for reducing chromosomal instability in cancer cells
CN113341154B (zh) * 2021-05-14 2024-11-05 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
IL310863A (en) 2021-08-26 2024-04-01 Volastra Therapeutics Inc Spiro indoline inhibitors of kif18a
CN115354078B (zh) * 2022-09-02 2023-07-07 中山大学附属第一医院 骨肉瘤检测标记物及其应用
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2015036643A2 (es) 2013-09-13 2015-03-19 Sierra Jiménez Angels Marcador para predecir metástasis del cancer de mama
BR112016020897A2 (en) * 2014-03-11 2018-01-23 The Council Of The Queensland Institute Of Medical Research Determination of cancer aggressiveness, prognosis, and responsiveness to treatment
JP6898848B2 (ja) * 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法
WO2016176222A1 (en) 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
AU2018300007A1 (en) 2017-07-10 2020-02-27 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment

Also Published As

Publication number Publication date
SG11202000132WA (en) 2020-02-27
US11821042B2 (en) 2023-11-21
MX2020000406A (es) 2020-10-01
US20240110246A1 (en) 2024-04-04
WO2019014246A1 (en) 2019-01-17
AU2018300007A1 (en) 2020-02-27
EP3652349A1 (en) 2020-05-20
JP7197556B2 (ja) 2022-12-27
BR112020000477A2 (pt) 2020-07-21
US20210130903A1 (en) 2021-05-06
KR20200037796A (ko) 2020-04-09
CN111295454A (zh) 2020-06-16
IL271849A (en) 2020-02-27
JP2020526206A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
US20240110246A1 (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
US11873486B2 (en) Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
US20230203485A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
US12043870B2 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20230075965A1 (en) Uses of biomarkers for improving immunotherapy
US20240018242A1 (en) Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2019178217A1 (en) Methods and compositions for treating, diagnosing, and prognosing cancer
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
US20240052028A1 (en) Enhancement of anti-tumor phagocytosis
US20230105008A1 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
US20240280561A1 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024500064A (ja) チェックポイント阻害剤療法に対する耐性を決定する方法
EP3743058A1 (en) Methods for predicting tumor response to immunotherapy
WO2019014664A1 (en) MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
KR20230165212A (ko) 적혈구 장애의 치료 방법
US20250114454A1 (en) Modified immune cells and methods for use thereof
US20260117178A1 (en) Means to treat autoimmunity by refining regulatory t cells
Licenziato IMMUNO-ONCOLOGY PROFILING IN CANINE CANCERS
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707